2024 г
 Safety and specific activity of the recombinant SARS-CoV-2 allergen (“CoronaDerm-PS”) based on phase I–II clinical trial results
  Russian Journal of Infection and Immunity. – 2024. – Т. 14. – №. 5. – С. 900-916
   Savin T.V., Milichkina A.M., Krasnov A.A., Kuznetsova R.N., Shchederkina E.E., Svarval A.V., Sharova A.А., Reingardt D.E., Ostankova Y.V., Gubanova A.V., Petrova O.A., Zhimbaeva O.B., Razumovskaya A.P., Drozd I.V., Rubinstein A.А., Trulev A.S., Kudryavtsev I.V., Riabchenkova A.A., Chirak E.L., Chirak E.R., Saenko A.I., Kopat V.V., Dukhovlinov I.V., Simbirtsev A.S., Totolian A.A.